rate of PID following gonorrhoea infection. This analysis compares the rate of hospitalisation for PID following a diagnosis of gonorrhoea to the rate following a chlamydia diagnosis.

**Method** All women, aged 15–45 years, in New South Wales (NSW), with a diagnosis of chlamydia or gonorrhoea between 1/7/2000 and 31/12/2008 were followed for up to one year after diagnosis for hospitalisations for PID. The incidence rates of PID hospitalisation among women with a chlamydia or gonorrhoea diagnosis were compared to the whole of the NSW population using standardised incidence ratios (SIRs). Poisson regression was used to compare the rates of PID hospitalisation after adjusting for age, diagnosis date, socioeconomic group, area of residence and prior births.

**Results** There were 38379 women with a chlamydia diagnosis. During 35014 person years of follow-up (PYFU), 485 were hospitalised for PID; incidence rate (IR) 13.8 per 1000 PYFU (95% CI 12.6–15.1). Among 1023 women with a gonorrhoea diagnosis, during 295 PYFU 45 were hospitalised for PID; (IR 50.3 per 1000 PYFU, 95% CI 35.6–65.0). Compared to the age-equivalent NSW female population, the incidence of PID hospitalisation was 27.0 (95% CI 24.4–29.8) times greater among women who had a chlamydia diagnosis in the year prior to hospitalisation and 95.8 (95% CI 64.2–137.6) times greater among women with a gonorrhoea diagnosis. Younger age, diagnosis prior to 2005, socioeconomic disadvantage and prior births were also associated with an increased rate of PID hospitalisation.

**Conclusion** Hospitalisation rates for PID were over 3 times greater in women diagnosed with gonorrhoea than chlamydia, and rates in both were substantially higher than in the general female population. Our results suggest that gonorrhoea causes more serious reproductive health sequelae than chlamydia.

**P3.012** HOW ROBUST ARE THE DESCRIPTIONS OF CHLAMYDIA NATURAL HISTORY USED IN ECONOMIC EVALUATIONS OF CONTROL STRATEGIES?


1B Davies, 2S Anderson, 3K M E Turner, 4H Ward. 1Imperial College London, London, UK, 2University of Bristol, Bristol, UK

**Background** The decision to implement a Chlamydia screening programme is based on a detailed assessment of its projected impact and cost-effectiveness. In the absence of evidence from randomised controlled trials, transmission dynamic models are crucial to this process. However these models are highly sensitive to the representation of the infection. We review the evidence used to inform the model parameters highlighting their strengths and limitations.

**Methods** Published economic analyses of chlamydia screening interventions were identified following a systematic search of the literature. Only transmission dynamic models were included as they represent the gold standard. Parameters describing chlamydia infection were extracted and the variability across the studies assessed. The data used to inform each parameter was sourced and critically evaluated.

**Results** Eleven studies were included in this review, all evaluating chlamydia screening programme designs in developed countries. Many key natural history parameters are based on sparse historical data and there is wide variation in the values used across the models. For example,

- The per act transmission probability ranging from 3.75% to 15.3%
- The modelled duration of asymptomatic infection was between 180–570 days in women and 40–200 days in men.
- Only one paper includes a period of protective immunity following infection.
- Only 2 studies consider the role of reinfection in the development of complications
- However, there is a general consensus in the proportion of people that are asymptomatic, between 70–75% of women and 25–50% of men.

**Conclusion** We highlight the variability in descriptions of the natural history and emphasise the importance of using contemporary data to inform modelling studies. A clear consensus on the appropriate representation of the natural history is needed, with estimates continuously updated using new evidence.

**P3.013** THE ROLE OF CHLAMYDIA IN PELVIC INFLAMMATORY DISEASE AND ECCOPTIC PREGNANCY


1M Price, 2A Ades, 3N Welton, 4K Soldan, 5P Horner. 1University of Birmingham, Birmingham, UK, 2University of Bristol, Bristol, UK, 3Health Protection Agency, London, UK, 4University of Bristol, Bristol, UK